Refine your search:     
Report No.
 - 
Search Results: Records 1-8 displayed on this page of 8
  • 1

Presentation/Publication Type

Initialising ...

Refine

Journal/Book Title

Initialising ...

Meeting title

Initialising ...

First Author

Initialising ...

Keyword

Initialising ...

Language

Initialising ...

Publication Year

Initialising ...

Held year of conference

Initialising ...

Save select records

Journal Articles

Assessment of olfactory nerve by SPECT-MRI image with nasal thallium-201 administration in patients with olfactory impairments in comparison to healthy volunteers

Shiga, Hideaki*; Taki, Junichi*; Washiyama, Koshin*; Yamamoto, Jumpei*; Kinase, Sakae; Okuda, Koichi*; Kinuya, Seigo*; Watanabe, Naoto*; Tonami, Hisao*; Koshida, Kichiro*; et al.

PLOS ONE (Internet), 8(2), p.e57671_1 - e57671_8, 2013/02

 Times Cited Count:14 Percentile:67.39(Multidisciplinary Sciences)

Journal Articles

Internal dosimetry for nasal thallium-201 administration

Kinase, Sakae; Washiyama, Koshin*; Shiga, Hideaki*; Taki, Junichi*; Nakanishi, Yusuke*; Koshida, Kichiro*; Miwa, Takaki*; Kinuya, Seigo*; Amano, Ryohei*

KEK Proceedings 2012-7, p.35 - 40, 2012/10

no abstracts in English

Journal Articles

Preparation and evaluation of $$^{186/188}$$Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site

Ogawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Onoguchi, Masahisa*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Odani, Akira*; Saji, Hideo*

Annals of Nuclear Medicine, 23(10), p.843 - 848, 2009/12

 Times Cited Count:9 Percentile:33.73(Radiology, Nuclear Medicine & Medical Imaging)

Rhenium is one of the most valuable elements for internal radiotherapy because $$^{186/188}$$Re have favorable physical characteristics. However, there are problems when proteins such as antibodies are used as carriers of $$^{186/188}$$Re. Labeling methods require the complicated processes. Therefore, we planned the preparation by a simple method and evaluation of a stable $$^{186/188}$$Re-labeled antibody. For this purpose, we selected $$^{186/188}$$Re(I) tricarbonyl complex as a chelating site. A7 was used as a model protein. $$^{186/188}$$Re-labeled A7 was prepared by directly reacting a $$^{186/188}$$Re(I) tricarbonyl precursor with A7. $$^{186/188}$$Re-(CO)$$_{3}$$-A7 were prepared with radiochemical yields of 23-28%. After purification, $$^{186/188}$$Re-(CO)$$_{3}$$-A7 showed a radiochemical purity of over 95%. In biodistribution experiments, $$^{186/188}$$Re-labeled A7 showed high uptakes in the tumor.

Journal Articles

Therapeutic effects of a $$^{186}$$Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model

Ogawa, Kazuma*; Mukai, Takahiro*; Asano, Daigo*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*

Journal of Nuclear Medicine, 48(1), p.122 - 127, 2007/01

We developed a highly stable rhenium-186 ($$^{186}$$Re)-MAG3 complex-conjugated bisphosphonate, ($$^{186}$$Re-MAG3-HBP), for the treatment of painful bone metastases. This agent showed a superior biodistribution as a bone-seeking agent in normal mice when compared with $$^{186}$$Re-HEDP. In this study, we evaluated the therapeutic effects of $$^{186}$$Re-MAG3-HBP using an animal model of bone metastasis. In the rats treated with $$^{186}$$Re-HEDP, tumor growth was comparable to that in untreated rats. In contrast, when $$^{186}$$Re-MAG3-HBP was administered, tumor growth was significantly inhibited. Allodynia induced by bone metastasis was attenuated by treatment with $$^{186}$$Re-MAG3-HBP or $$^{186}$$Re-HEDP, but $$^{186}$$Re-MAG3-HBP tended to be more effective. These results indicate that $$^{186}$$Re-MAG3-HBP could be useful as a therapeutic agent for the palliation of metastatic bone pain.

Journal Articles

Experimental radioimmunotherapy with $$^{186}$$Re-MAG3-A7 anti-colorectal cancer monoclonal antibody; Comparison with $$^{131}$$I-counterpart

Kinuya, Seigo*; Yokoyama, Kunihiko*; Kobayashi, Katsutoshi; Motoishi, Shoji; Onoma, Katsuyuki; Watanabe, Naoto*; Shuke, Noriyuki*; Bunko, Hisashi*; Nichigishi, Takatoshi*; Tonami, Norihisa*

Annals of Nuclear Medicine, 15(3), p.199 - 202, 2001/06

 Times Cited Count:9 Percentile:32.17(Radiology, Nuclear Medicine & Medical Imaging)

no abstracts in English

Journal Articles

Methylxanthine sensitization of human colon cancer cells to $$^{186}$$Re-labeled monoclonal antibody

Kinuya, Seigo*; Yokoyama, Kunihiko*; Kudo, Miho*; Kasahara, Yoshihito*; Kobayashi, Katsutoshi; Motoishi, Shoji; Onoma, Katsuyuki; Bunko, Hisashi*; Nichigishi, Takatoshi*; Tonami, Norihisa*

Journal of Nuclear Medicine, 42(4), p.596 - 600, 2001/04

no abstracts in English

Oral presentation

Preparation of $$^{188}$$Re-labeled antibody (A7) by a simple method using rhenium(I) tricarbonyl complex

Ogawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Yoshimoto, Mitsuyoshi*; Shiba, Kazuhiro*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*

no journal, , 

$$^{188}$$Re is one of the most useful radionuclides for internal radiotherapy. However, there is a problem when protein such as antibody is used as a carrier of $$^{188}$$Re. The labeling method using bifunctional chelating agents require the conjugation of $$^{188}$$Re-complex to protein after radiolabeling with the bifunctional chelating agent. Then, we planned the preparation of a stable $$^{188}$$Re-labeled protein by a simple method. A7 monoclonal antibody was labeled by reacting $$^{188}$$Re(I) tricarbonyl precursor with A7 directly. $$^{188}$$Re labeled A7 was prepared with radiochemical yield of 23%. After purification, $$^{188}$$Re labeled A7 showed radiochemical purity over 98%. After 24 hours of incubation, about 93% of $$^{188}$$Re-A7 remained intact, which indicates $$^{188}$$Re-A7 is stable in vitro. In biodistribution experiment, 11.2% of the injected dose/g of $$^{188}$$Re-A7 accumulated in the tumor at 24 hours postinjection, and tumor to blood ratio was over 1.0 at the same time.

Oral presentation

Evaluation of S values for organs from nasal administration of Tl-201

Kinase, Sakae; Washiyama, Koshin*; Shiga, Hideaki*; Taki, Junichi*; Nakanishi, Yusuke*; Koshida, Kichiro*; Miwa, Takaki*; Kinuya, Seigo*; Amano, Ryohei*

no journal, , 

no abstracts in English

8 (Records 1-8 displayed on this page)
  • 1